NEC Corporation (NEC; TSE: 6701) and Biomy, Inc. (Biomy) have signed a Memorandum of Understanding (MoU) to form a joint marketing partnership aimed at advancing artificial intelligence and deep learning (AI/DL)-based analytical platforms in digital pathology. This collaboration seeks to enhance precision medicine for cancer patients and drive innovation within the healthcare industry.

Transforming Digital Pathology with AI

The partnership integrates NEC’s expertise in image analysis and healthcare technologies with Biomy’s proprietary AI-driven DeepPathFinder™ platform. This platform leverages AI/DL to automate the analysis of digital pathology images, enabling the detection of immune cells, spatial biology features, and drug efficacy-related characteristics—all from hematoxylin and eosin (H&E)-stained images.

Objectives of the Partnership

Through this partnership, NEC and Biomy aim to:

• Enhance Pathology Analysis: Leverage AI/DL technologies to discover new pathological biomarkers for more precise diagnostics.
• Deliver Comprehensive Services: Offer advanced digital pathology platforms and biomarker discovery services to pharmaceutical and biotech companies, as well as academia.
• Streamline Regulatory Approvals: Provide guidance for regulatory processes to enable the clinical adoption of AI-powered medical devices.

Revolutionizing Cancer Care

With AI and deep learning at its core, the partnership aims to accelerate the discovery of pathological biomarkers, allowing healthcare providers to tailor treatments to individual patients. The resulting platform will enhance efficiency and accuracy in digital pathology, significantly benefiting cancer care.

NEC and Biomy are committed to advancing AI/DL-based pathology platforms and facilitating the adoption of newly developed pathological biomarkers in clinical settings. This partnership underscores a shared vision to deliver transformative healthcare solutions and improve outcomes for cancer patients worldwide